HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia.

Allogeneic hematopoietic cell transplantation Bulk/single cell transcriptomics HLA class II immunopeptidome HLA-DM HLA-DO Hematological malignancies

Journal

Best practice & research. Clinical haematology
ISSN: 1532-1924
Titre abrégé: Best Pract Res Clin Haematol
Pays: Netherlands
ID NLM: 101120659

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 29 03 2024
revised: 13 05 2024
accepted: 27 06 2024
medline: 5 8 2024
pubmed: 5 8 2024
entrez: 4 8 2024
Statut: ppublish

Résumé

HLA class II antigen presentation is modulated by the activity of the peptide editor HLA-DM and its antagonist HLA-DO, with their interplay controlling the peptide repertoires presented by normal and malignant cells. The role of these molecules in allogeneic hematopoietic cell transplantation (alloHCT) is poorly investigated. Balanced expression of HLA-DM and HLA-DO can influence the presentation of leukemia-associated antigens and peptides targeted by alloreactive T cells, therefore affecting both anti-leukemia immunity and the potential onset of Graft versus Host Disease. We leveraged on a large collection of bulk and single cell RNA sequencing data, available at different repositories, to comprehensively review the level and distribution of HLA-DM and HLA-DO in different cell types and tissues of the human body. The resulting expression atlas will help future investigations aiming to dissect the dual role of HLA class II peptide editing in alloHCT, and their potential impact on its clinical outcome.

Identifiants

pubmed: 39098801
pii: S1521-6926(24)00027-6
doi: 10.1016/j.beha.2024.101561
pii:
doi:

Substances chimiques

HLA-DM antigens 0
HLA-D Antigens 0
HLA-DO antigens 0
Peptides 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101561

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Bettina Budeus (B)

Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany. Electronic address: Bettina.Budeus@uk-essen.de.

Miguel Álvaro-Benito (M)

School of Medicine, Universidad Complutense de Madrid, 12 de Octubre Health Research Institute, Madrid, Spain; Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. Electronic address: migalv07@ucm.es.

Pietro Crivello (P)

Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany. Electronic address: pietro.crivello@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH